메뉴 건너뛰기




Volumn 73, Issue 1, 2014, Pages 48-55

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CORTICOSTEROID; LEFLUNOMIDE; METHOTREXATE; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

EID: 84889668023     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203696     Document Type: Article
Times cited : (407)

References (34)
  • 1
    • 84875956855 scopus 로고    scopus 로고
    • High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires
    • Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 2013;72:736-40.
    • (2013) Ann Rheum Dis , vol.72 , pp. 736-740
    • Haroon, M.1    Kirby, B.2    Fitzgerald, O.3
  • 2
    • 84885601493 scopus 로고    scopus 로고
    • Prevalence of rheumatologist-diagnosed psoriatic arthritis in psoriasis patients in European/North American dermatology clinics
    • In press
    • Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist- diagnosed psoriatic arthritis in psoriasis patients in European/North American dermatology clinics. J Am Acad Dermatol 2013 In press.
    • (2013) J Am Acad Dermatol
    • Mease, P.J.1    Gladman, D.D.2    Papp, K.A.3
  • 3
    • 0345099477 scopus 로고    scopus 로고
    • A prospective, clinical and radiological study of early psoriatic arthritis: An early synovitis clinic experience
    • DOI 10.1093/rheumatology/keg384
    • Kane D, Stafford L, Bresnihan B, et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003;42:1460-68. (Pubitemid 37508919)
    • (2003) Rheumatology , vol.42 , Issue.12 , pp. 1460-1468
    • Kane, D.1    Stafford, L.2    Bresniham, B.3    FitzGerard, O.4
  • 4
    • 0025800559 scopus 로고
    • Psoriatic Athritis (PA): A clinical immunological and radiological study of 180 patients
    • Alonso JCT, Perez AR, Castrillo JMA, et al. Psoriatic athritis (PA): a clinical, immunological and radiological study of 180 patients. Rheumatology (Oxford) 1991;30:245-50.
    • (1991) Rheumatology (Oxford) , vol.30 , pp. 245-250
    • Alonso, J.C.T.1    Perez, A.R.2    Castrillo, J.M.A.3
  • 5
    • 0032729645 scopus 로고    scopus 로고
    • The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: A type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients
    • Austin LM, Ozawa M, Kikuchi T, et al. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999;113:752-9.
    • (1999) J Invest Dermatol , vol.113 , pp. 752-759
    • Austin, L.M.1    Ozawa, M.2    Kikuchi, T.3
  • 6
  • 8
    • 0034729950 scopus 로고    scopus 로고
    • Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
    • Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90. (Pubitemid 30487495)
    • (2000) Lancet , vol.356 , Issue.9227 , pp. 385-390
    • Mease, P.J.1    Goffe, B.S.2    Metz, J.3    Vanderstoep, A.4    Finck, B.5    Burge, D.J.6
  • 9
    • 65249137637 scopus 로고    scopus 로고
    • Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study
    • Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
    • (2009) Arthritis Rheum , vol.60 , pp. 976-986
    • Kavanaugh, A.1    McInnes, I.2    Mease, P.3
  • 11
    • 84857238069 scopus 로고    scopus 로고
    • A systematic literature review of drug therapies for the treatment of psoriatic arthritis: Current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis
    • Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71:319-26.
    • (2012) Ann Rheum Dis , vol.71 , pp. 319-326
    • Ash, Z.1    Gaujoux-Viala, C.2    Gossec, L.3
  • 13
    • 67449124634 scopus 로고    scopus 로고
    • Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: The RAPID 2 study A randomised controlled trial
    • Smolen J, Landewé RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797.
    • (2009) Ann Rheum Dis , vol.68 , pp. 797
    • Smolen, J.1    Landewé, R.B.2    Mease, P.3
  • 14
    • 55849112632 scopus 로고    scopus 로고
    • Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
    • Keystone E, van der Heijde D, Mason D, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29.
    • (2008) Arthritis Rheum , vol.58 , pp. 3319-3329
    • Keystone, E.1    Van Der Heijde, D.2    Mason, D.3
  • 15
    • 84870317631 scopus 로고    scopus 로고
    • Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: Results from the phase IIIb REALISTIC study
    • Weinblatt M, Fleischmann R, Huizinga TW, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the phase IIIb REALISTIC study. Rheumatology (Oxford) 2012;51:2204-14.
    • (2012) Rheumatology (Oxford) , vol.51 , pp. 2204-2214
    • Weinblatt, M.1    Fleischmann, R.2    Huizinga, T.W.3
  • 16
    • 84863336589 scopus 로고    scopus 로고
    • Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab0 certolizumab pegol: Results of a phase II randomized, placebo-controlled trial with a re-treatment extension
    • Reich K, Ortonne JP, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab0 certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol 2012;167:180-90.
    • (2012) Br J Dermatol , vol.167 , pp. 180-190
    • Reich, K.1    Ortonne, J.P.2    Gottlieb, A.B.3
  • 17
    • 33746951437 scopus 로고    scopus 로고
    • Classification criteria for psoriatic arthritis: Development of new criteria from a large international study
    • DOI 10.1002/art.21972
    • Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73. (Pubitemid 44205029)
    • (2006) Arthritis and Rheumatism , vol.54 , Issue.8 , pp. 2665-2673
    • Taylor, W.1    Gladman, D.2    Helliwell, P.3    Marchesoni, A.4    Mease, P.5    Mielants, H.6
  • 18
    • 0029044362 scopus 로고
    • American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis
    • Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38: 727-35.
    • (1995) Arthritis Rheum , vol.38 , pp. 727-735
    • Felson, D.T.1    Anderson, J.J.2    Boers, M.3
  • 21
    • 84889657887 scopus 로고    scopus 로고
    • Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: The RAPID-PsA 24-week phase 3 double-blind randomized placebo-controlled study of certolizumab pegol
    • van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: the RAPID-PsA 24-week phase 3 double-blind randomized placebo-controlled study of certolizumab pegol. Ann Rheum Dis 2014;73: 233-7.
    • (2014) Ann Rheum Dis , vol.73 , pp. 233-237
    • Van Der Heijde, D.1    Fleischmann, R.2    Wollenhaupt, J.3
  • 22
    • 0018099294 scopus 로고
    • Severe psoriasis - oral therapy with a new retinoid
    • Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978;157:238-44. (Pubitemid 8387357)
    • (1978) Dermatologica , vol.157 , Issue.4 , pp. 238-244
    • Fredriksson, T.1    Pettersson, U.2
  • 23
    • 80855151628 scopus 로고    scopus 로고
    • Measures of psoriatic arthritis: Tender and swollen joint assessment, psoriasis area and severity index (PASI), nail psoriasis severity index (NAPSI), modified nail psoriasis severity index (mNAPSI), mander/newcastle enthesitis index (MEI), leeds enthesitis index (LEI), spondyloarthritis research consortium of canada (SPARCC), maastricht ankylosing spondylitis enthesis score (MASES)
    • Composite psoriatic disease activity index (CPDAI), psoriatic arthritis joint activity index (PsAJAI), disease activity in psoriatic arthritis (DAPSA), psoriatic arthritis response criteria (PsARC), functional assessment of chronic illness therapy-fatigue (FACIT-F), psoriatic arthritis quality of life (PsAQOL), leeds dactylitis index (LDI), patient global for psoriatic arthritis, dermatology life quality index (DLQI)
    • Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res 2011;63(Suppl 11):S64-85.
    • (2011) Arthritis Care Res , vol.63 , Issue.SUPPL. 11
    • Mease, P.J.1
  • 24
    • 2042519830 scopus 로고    scopus 로고
    • Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of veterans affairs cooperative study
    • Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of veterans affairs cooperative study. Arthritis Rheum 1996;39:2013-20.
    • (1996) Arthritis Rheum , vol.39 , pp. 2013-2020
    • Clegg, D.O.1    Reda, D.J.2    Mejias, E.3
  • 26
    • 73449100479 scopus 로고    scopus 로고
    • Defining minimal disease activity in psoriatic arthritis: A proposed objective target for treatment
    • Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69: 48-53.
    • (2010) Ann Rheum Dis , vol.69 , pp. 48-53
    • Coates, L.C.1    Fransen, J.2    Helliwell, P.S.3
  • 27
    • 77954259617 scopus 로고    scopus 로고
    • Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data
    • Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res 2010;62:965-69.
    • (2010) Arthritis Care Res , vol.62 , pp. 965-969
    • Coates, L.C.1    Helliwell, P.S.2
  • 28
    • 77954304374 scopus 로고    scopus 로고
    • Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort
    • Coates LC, Cook R, Lee K-A, et al. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res 2010;62:970-76.
    • (2010) Arthritis Care Res , vol.62 , pp. 970-976
    • Coates, L.C.1    Cook, R.2    Lee, K.-A.3
  • 29
    • 79955432850 scopus 로고    scopus 로고
    • (accessed Feb 2013)
    • EMA. Annex 1: Summary of Product Characteristics (Humira). 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000481/WC500050870.pdf (accessed Feb 2013).
    • (2013) Annex 1: Summary of Product Characteristics (Humira)
  • 30
    • 84946650481 scopus 로고
    • Probable inference, the law of succession, and statistical inference
    • Wilson E. Probable inference, the law of succession, and statistical inference. J Am Stat Association 1927;22:209-12.
    • (1927) J Am Stat Association , vol.22 , pp. 209-212
    • Wilson, E.1
  • 32
    • 84865186509 scopus 로고    scopus 로고
    • A randomized placebo-controlled trial of methotrexate in psoriatic arthritis
    • Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 2012;51:1368-77.
    • (2012) Rheumatology , vol.51 , pp. 1368-1377
    • Kingsley, G.H.1    Kowalczyk, A.2    Taylor, H.3
  • 33
    • 85019299554 scopus 로고    scopus 로고
    • Clinical response, drug survival and predictors thereof among 548 switchers of tumor necrosis factor alpha inhibitor therapy in psoriatic arthritis results from the danish nationwide danbio registry (abstract)
    • Glintborg B. Clinical response, drug survival and predictors thereof among 548 switchers of tumor necrosis factor alpha inhibitor therapy in psoriatic arthritis. Results from the Danish Nationwide Danbio Registry (abstract). Arthritis Rheum 2012;64(10 (Suppl)):S1081.
    • (2012) Arthritis Rheum , vol.64 , Issue.10 SUPPL.
    • Glintborg, B.1
  • 34
    • 84873581440 scopus 로고    scopus 로고
    • Ustekinumab in active psoriatic arthritis including patients previously treated with Anti-TNF agents: Results of a phase 3, multicenter, double-blind, placebo-controlled study
    • Ritchlin CT, Gottlieb AB, McInnes IB, et al. Ustekinumab in Active Psoriatic Arthritis Including Patients Previously Treated with Anti-TNF Agents: results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study. Arthritis Rheum 2012;64(10 (Suppl)):1080-81.
    • (2012) Arthritis Rheum , vol.64 , Issue.10 SUPPL. , pp. 1080-1081
    • Ritchlin, C.T.1    Gottlieb, A.B.2    McInnes, I.B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.